Trial Profile

Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lirilumab (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms EffiKIR
Sponsors Innate Pharma

Most Recent Events

12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
22 Nov 2017 According to an Innate Pharma media release, data from this trial will be discussed at the upcoming ASH Annual Meeting 2017.
06 Feb 2017 Top-line results published in an Innate Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com